Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run

Simply Wall St.09-02 23:16

Tango Therapeutics has produced very strong returns over the past year, yet the valuation picture is split, with the intrinsic value estimate pointing to a discount while market based multiples point ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664958843?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-09-02 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664958843","market":"sg","top_or_hot":-1,"title":"Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run","media":"Simply Wall St.","content":"<div>\n<p>Tango Therapeutics has produced very strong returns over the past year, yet the valuation picture is split, with the intrinsic value estimate pointing to a discount while market based multiples point ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-stock-looks-stretched-after-its-236\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-02 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-stock-looks-stretched-after-its-236><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tango Therapeutics has produced very strong returns over the past year, yet the valuation picture is split, with the intrinsic value estimate pointing to a discount while market based multiples point ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-stock-looks-stretched-after-its-236\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-stock-looks-stretched-after-its-236","article_id":"2664958843","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-stock-looks-stretched-after-its-236","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2664958843","pubTimestamp":1788362216,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tango Therapeutics has produced very strong returns over the past year, yet the valuation picture is split, with the intrinsic value estimate pointing to a discount while market based multiples point the other way.\n\nOver the past 12 months Tango Therapeutics has returned 235.6%, which puts a lot more weight on whether that price now sits above or below a fair estimate of value.\nExpectations for future cash generation from Tango Therapeutics' oncology pipeline can support the current...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TNGX":"Tango Therapeutics Inc.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Tango Therapeutics (TNGX) 股价在上涨 236% 后看起来捉襟见肘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"TNGX":1.5},"content_text":"Tango Therapeutics has produced very strong returns over the past year, yet the valuation picture is split, with the intrinsic value estimate pointing to a discount while market based multiples point the other way.  Over the past 12 months Tango Therapeutics has returned 235.6%, which puts a lot more weight on whether that price now sits above or below a fair estimate of value. Expectations for future cash generation from Tango Therapeutics' oncology pipeline can support the current valuation, while ongoing development risk and the timing of any commercial revenue remain key constraints on how much value investors may be willing to assign today. The broader checks produce a mixed picture rather than a clear bargain or clear overvaluation, with Tango Therapeutics scoring 3 out of 6 on value tests.  The issue now is whether the current share price of Tango Therapeutics already reflects the intrinsic value suggested by the Discounted Cash Flow model or whether there is still a material gap. Balance Tango Therapeutics' sharp 235.6% one year return by comparing it with other hand picked high quality value ideas in 50 high quality undervalued stocks AdvertisementIs Tango Therapeutics Still Cheap on Cash Flow? The Discounted Cash Flow (DCF) model values Tango Therapeutics by projecting future free cash flows and discounting them back to today. Tango Therapeutics currently reports last twelve month free cash flow of a loss of $144.8 million, so the model relies heavily on expectations that cash generation from the oncology pipeline recovers over time rather than current profitability. Under these projections, free cash flow is assumed to move from losses into positive territory and then grow, which produces an estimated intrinsic value of about $44.02 per share. Compared with the current share price this implies the stock trades at a 49.2% discount to the DCF estimate. In other words, the market price and the cash flow model are telling two different stories about what Tango Therapeutics might be worth. On this DCF view, Tango Therapeutics stock currently screens as undervalued relative to its projected future cash flows. Our Discounted Cash Flow (DCF) analysis suggests Tango Therapeutics is undervalued by 49.2%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks. TNGX Discounted Cash Flow as at Sep 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Tango Therapeutics. Does Tango Therapeutics Look Pricey on Book Value? For Tango Therapeutics, the price to book ratio is a useful cross check because the company is still in a development phase and earnings are not yet a clear anchor. The stock currently trades on a P/B of about 3.7x, compared with an industry average for biotechs of roughly 2.5x and a peer group level near 4.8x. That means Tango Therapeutics is priced above the broader biotech sector on this metric, although it sits below the peer average that focuses on closer comparables. Given that premium to the wider industry, the P/B multiple suggests investors are already paying up for Tango Therapeutics relative to many other biotech stocks, even after considering its specialist oncology focus and early stage profile. On the P/B measure, Tango Therapeutics stock currently appears overvalued compared with the broader biotech sector. NasdaqGM:TNGX P/B Ratio as at Sep 2026 See what the numbers say about this price — find out in our valuation breakdown. The Tango Therapeutics Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where the valuation puzzle for Tango Therapeutics leaves off. They spell out the specific paths for growth, margins and earnings that would need to play out for Tango Therapeutics' stock to be worth materially more or less than today's price, and instead of relying on a single multiple or model, each one lays out its own assumptions so you can compare them with future results as they come through. Share a narrative on Tango Therapeutics' stock to present your own numbers-driven view on where its growth, margins and execution go from here. Add your voice to the Simply Wall St community and see how your thesis holds up as new results arrive over time. Do you think there's more to the story for Tango Therapeutics? Head over to our Community to see what others are saying! The Bottom Line For Tango Therapeutics, the Discounted Cash Flow (DCF) view points to an intrinsic value estimate above the current share price, while the market multiple view flags the stock as overvalued compared with the broader biotech sector. That mixed signal is consistent with the broader checks, which do not give a clear green light or red flag. The key question is whether future cash generation from the oncology pipeline ultimately supports the intrinsic value estimate, or whether ongoing development risk means the current premium to sector book values already reflects that. How that trade off resolves is likely to define whether today’s apparent discount is an opportunity or a caution signal.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tango Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664958843","isCrawlerRequest":true}